Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment. Elekta also provides oncology information systems and treatment planning software that enable seamless integration of imaging, planning and delivery for multidisciplinary clinical teams. In addition, the company offers comprehensive service and support programs, clinical training and educational resources to ensure optimal system performance and professional development for its customers.

Founded in 1972 by Swedish neurosurgeon Lars Leksell, Elekta pioneered stereotactic radiosurgery and has since grown into a worldwide provider of precision cancer care technologies. Headquartered in Stockholm, Sweden, the company serves hospitals, cancer centers and clinics across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa. Elekta maintains regional offices and service centers to support installation, maintenance and training programs in key markets around the globe.

Guided by a leadership team of experienced executives and a board of directors with deep expertise in healthcare technology, Elekta continues to invest in research and development to advance treatment efficacy and patient quality of life. The company collaborates with academic institutions, clinical partners and industry stakeholders to drive innovation in radiotherapy and radiosurgery and to shape the future of precision cancer care.

Key Stats

• Today's Range: $4.87 to $4.97
• 50-Day Range: $4.75 to $5.38
• 52-Week Range: $4.36 to $6.82
• Volume: 4,143 shs
• Average Volume: 2,466 shs
• Market Capitalization: $1.83 billion
• P/E Ratio: 82.68
• Dividend Yield: 2.62%
• Price Target: N/A
• Consensus Rating: Reduce

Elekta Stock Analysis - MarketRank™

Elekta scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elekta.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 19.44%

Earnings Growth

Earnings for Elekta are expected to grow by 19.44% in the coming year, from $0.36 to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elekta is 82.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 231.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elekta is 82.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.05.

Price to Book Value per Share Ratio

Elekta has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Elekta pays a meaningful dividend of 2.57%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elekta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Elekta is 216.67%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Elekta will have a dividend payout ratio of 30.23% next year. This indicates that Elekta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.47

News Sentiment

Elekta has a news sentiment score of -0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Elekta this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elekta insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.28% of the stock of Elekta is held by insiders. A high percentage of insider ownership can be a sign of company health.

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta's stock was trading at $5.66 on January 1st, 2025. Since then, EKTAY shares have decreased by 12.4% and is now trading at $4.96.

How were Elekta's earnings last quarter?

Elekta AB (OTCMKTS:EKTAY) released its quarterly earnings results on Thursday, August, 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $379.64 million for the quarter. Elekta had a trailing twelve-month return on equity of 11.49% and a net margin of 1.40%.

How do I buy shares of Elekta?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/28/2025
• Ex-Dividend for 9/26 Dividend: 9/08/2025
• Record date for 9/26 Dividend: 9/09/2025
• Dividend Payable: 9/26/2025
• Today: 10/14/2025
• Next Earnings (Estimated): 11/26/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,718
• Year Founded: 1972

Profitability

• EPS (Trailing Twelve Months): $0.06
• Trailing P/E Ratio: 17.89
• Forward P/E Ratio: 13.78
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: 1.40%
• Pretax Margin: 3.03%
• Return on Equity: 11.49%
• Return on Assets: 3.65%

Debt

• Debt-to-Equity Ratio: 0.63
• Current Ratio: 1.05
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.07
• Cash Flow: $0.61 per share
• Price / Cash Flow: 8.18
• Book Value: $2.19 per share
• Price / Book: 2.26

Miscellaneous

• Outstanding Shares: 368,590,000
• Free Float: 216,435,000
• Market Cap: $1.83 billion
• Optionable: Not Optionable
• Beta: 1.12